用非布司他治疗时需要注意什么？

The US FDA has approved the first gout drug for the treatment of hyperuricemia in nearly 40 years - Takeda Pharmaceutical's febuxostat (febuxostat, feburic). Febuxostat (febuxostat, feburic) improves gout symptoms by lowering uric acid levels in the patient's blood. In addition, Takeda Pharmaceuticals North America is the independent developer and marketer of this product in the U.S. market. According to a statement from Takeda: The structure of this product is completely different from the xanthine oxidase inhibitor drugs developed 40 years ago. It is a new and highly effective non-purinic xanthine oxidase selective inhibitor. Xanthine oxidase is the key enzyme that promotes the production of uric acid. Febuxostat (febuxostat, feburic) can reduce uric acid levels in the blood of patients with hyperuricemic gout. The safety and effectiveness of febuxostat (febuxostat, feburic) have been proven in clinical studies, and no dose adjustment is required in patients with moderate or severe hepatic and renal insufficiency. The dosage of this product is 40 mg or 80 mg once daily, but this product is not recommended for patients with gout who do not have hyperuricemia.

What should I pay attention to when treating with febuxostat (febuxostat, feburic)? Gout attacks: An increase in the frequency of gout attacks is common during the early stages of taking febuxostat (febuxostat, feburic). This is because blood uric acid concentration decreases, leading to mobilization of urate deposited in tissues. To prevent gout attacks during the initial stages of treatment, it is recommended to take nonsteroidal anti-inflammatory drugs or colchicine at the same time. If gout attacks during treatment with febuxostat, there is no need to discontinue febuxostat treatment. Gout should be treated accordingly according to the patient's specific situation. Cardiovascular events: In randomized controlled trials, cardiovascular thrombotic events (including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) occurred in patients treated with febuxostat (febuxostat) compared with allopurinol. Medium) has a higher probability, among which febuxostat (febuxostat, feburic) is 0.74/100 patient-years (95%CI: 0.36-1.37), and allopurinol is 0.60/100 patient-years (95% Cl:0.16-1.53). A causal relationship between febuxostat and cardiovascular thrombotic events has not been established. Pay attention to monitor the symptoms and signs of myocardial infarction and stroke when taking the drug.